Barbara Montanini
Overview
Explore the profile of Barbara Montanini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caputo A, Elisi G, Levati E, Barotti G, Sartini S, Wagner J, et al.
J Enzyme Inhib Med Chem
. 2025 Jan;
40(1):2440861.
PMID: 39749973
Antibiotic resistance stands as the foremost post-pandemic threat to public health. The urgent need for new, effective antibacterial treatments is evident. Protein-protein interactions (PPIs), owing to their pivotal role in...
2.
Cavazzini D, Levati E, Germani S, Ta B, Monica L, Bolchi A, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596383
The mutational drift of SARS-CoV-2 and the appearance of multiple variants, including the latest Omicron variant and its sub-lineages, has significantly reduced (and in some cases abolished) the protective efficacy...
3.
Cantarella S, Vezzoli M, Carnevali D, Morselli M, Zemke N, Montanini B, et al.
Nucleic Acids Res
. 2024 Jul;
52(16):9481-9500.
PMID: 39011896
Alu retrotransposons, which form the largest family of mobile DNA elements in the human genome, have recently come to attention as a potential source of regulatory novelties, most notably by...
4.
Hu M, Bonalumi F, Hoang M, Burattini M, Caputo A, Bollati V, et al.
Vascul Pharmacol
. 2024 Jul;
155:107326.
PMID: 38985639
No abstract available.
5.
Glieca S, Cavazzini D, Levati E, Garrapa V, Bolchi A, Franceschi V, et al.
Eur J Pharm Sci
. 2023 Oct;
191:106609.
PMID: 37838239
One of the strategies proposed for the neutralization of SARS-CoV-2 has been to synthetize small proteins able to act as a decoy towards the virus spike protein, preventing it from...
6.
Bonatti M, Pitozzi V, Caruso P, Pontis S, Pittelli M, Frati C, et al.
BMJ Open Respir Res
. 2023 Sep;
10(1).
PMID: 37730279
Background: Idiopathic pulmonary fibrosis (IPF) is an irreversible disorder with a poor prognosis. The incomplete understanding of IPF pathogenesis and the lack of accurate animal models is limiting the development...
7.
Storti M, Faietti M, Murgia X, Catozzi C, Minato I, Tatoni D, et al.
Respir Res
. 2023 Mar;
24(1):80.
PMID: 36922832
Background: Premature birth, perinatal inflammation, and life-saving therapies such as postnatal oxygen and mechanical ventilation are strongly associated with the development of bronchopulmonary dysplasia (BPD); these risk factors, alone or...
8.
Montali I, Ceccatelli Berti C, Morselli M, Acerbi G, Barili V, Pedrazzi G, et al.
J Hepatol
. 2023 Mar;
79(1):50-60.
PMID: 36893853
Background & Aims: In chronic HBV infection, elevated reactive oxygen species levels derived from dysfunctional mitochondria can cause increased protein oxidation and DNA damage in exhausted virus-specific CD8 T cells....
9.
Vezzoli M, de Llobet Cucalon L, Di Vona C, Morselli M, Montanini B, de la Luna S, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835038
Regulation of histone acetylation dictates patterns of gene expression and hence cell identity. Due to their clinical relevance in cancer biology, understanding how human embryonic stem cells (hESCs) regulate their...
10.
Caputo A, Sartini S, Levati E, Minato I, Elisi G, Di Stasi A, et al.
Antibiotics (Basel)
. 2022 Oct;
11(10).
PMID: 36290107
Bacterial resistance represents a major health problem worldwide and there is an urgent need to develop first-in-class compounds directed against new therapeutic targets. We previously developed a drug-discovery platform to...